A state court in Pennsylvania ruled today that plaintiffs could proceed with their state law "failure to warn" claims against the manufacturer of generic Reglan (marketed as "metoclopramide"). The manufacturer was trying to have the state law claims thrown out, arguing that the claims were preempted by federal law. Huge win for plaintiffs. 

Metoclopramide is known to cause tardive dyskinesia in up to 29% patients who take it for a long period of time. We are currently representing a woman who suffers from the devastating effects of tardive dyskinesia after over a decade of using metoclopramide. Elderly people and women are more likely to suffer from metoclopramide-related tardive dyskinesia.